Aura Biosciences, Inc. (AURA)
NGM · Healthcare · Biotechnology
Closing price as of 2026-08-12 · Source: TEK2day Finance
Key Metrics
About Aura Biosciences, Inc.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (28.6M) | (27.9M) | (27.2M) | (34.9M) |
| Net Income | (27.0M) | (26.1M) | (25.6M) | (33.7M) |
| Diluted EPS | $-0.47 | $-0.40 | N/A | $-0.50 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (60.3M) | (85.0M) | (96.1M) | (112.8M) |
| Net Income | (58.8M) | (76.4M) | (86.9M) | (106.2M) |
| Diluted EPS | $-1.96 | $-1.93 | $-1.75 | $-1.76 |